XWPharma Ltd. today announced that data from clinical research of XW10172, a new chemical entity (NCE) in development for the treatment of sleep disorders associated with neurodegenerative diseases and narcolepsy, has been accepted for poster and oral presentation at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting, which will be held virtually from June 10-13, 2021.
May 19, 2021
· 2 min read